OWA
CRSP icon

One Wealth Advisors’s CRISPR Therapeutics CRSP Stock Holding History

One Wealth Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-37
Closed -$1K – 191
2019
Q1 		$1K Buy
+37
New +$1.28K ﹤0.01% 526
2018
Q4 		– Sell
-37
Closed -$2K – 184
2018
Q3 		$2K Hold
37
– – ﹤0.01% 498
2018
Q2 		$2K Buy
+37
New +$2.11K ﹤0.01% 498

Other funds holding CRSP

VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

One Wealth Advisors's CRSP Position: Q2 2019 in Review

One Wealth Advisors sold out of CRISPR Therapeutics (CRSP) in Q2 2019, closing a stake of 37 shares — an estimated $1K sold.

One Wealth Advisors first reported a position in CRSP in Q2 2018 and held it in 3 quarters. The position peaked at $2K in Q3 2018. 181 funds tracked by Wall St. Rank hold CRSP as of Q2 2019.

  • One Wealth Advisors reported no remaining CRISPR Therapeutics position as of Q2 2019 after selling out during the quarter.
  • One Wealth Advisors sold 37 CRISPR Therapeutics shares in Q2 2019, an estimated $1K.
  • One Wealth Advisors first reported a position in CRISPR Therapeutics in Q2 2018 and held it in 3 quarters.
  • One Wealth Advisors's CRISPR Therapeutics position peaked at $2K in Q3 2018.
  • 181 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2019.

Based on One Wealth Advisors's 13F filing for Q2 2019, filed 14 Aug 2019.